Articles tagged with Lymphoma
A study of 11 patients with non-Hodgkin's lymphoma who have failed standard chemotherapy found that Zevalin was effective in inducing partial and complete responses in three patients. The treatment was well-tolerated, with side effects including thrombocytopenia and neutropenia.
Researchers found that most imaging scans are unnecessary and can be avoided by confirming medication delivery within 24 hours of indium 111-labeled Zevalin injection. This simplifies treatment and improves patient compliance.
Researchers found significantly higher risks of non-Hodgkin's lymphoma and multiple myeloma among HCV patients in Sweden. The risk increases with the duration of HCV infection, suggesting that long-lasting infection may contribute to cancer development.
A new radioactive antibody treatment called Bexxar has shown promising results in a study, rivaling traditional chemotherapy regimens for follicular lymphoma. The treatment achieved a 95% response rate and 75% complete remission in patients with advanced-stage disease.
A large-scale study found that frequent exposure to ultraviolet rays from the sun, lamps, and solariums reduces the risk of developing non-Hodgkin's lymphoma by 30-40%. Researchers analyzed responses from over 6,000 patients and healthy individuals in Sweden and Denmark.
A recent study found that only 37% of patients with colorectal cancer received adequate lymph node evaluation, highlighting the need for improved surgical care and pathologic assessment. Additionally, research on non-Hodgkin lymphoma and obesity suggests no association between body mass index and overall risk of either disease.
Research findings indicate that increased sun exposure is associated with improved melanoma survival, while decreased UV radiation exposure may lower non-Hodgkin lymphoma risk. These studies provide new evidence for the potential beneficial effects of sunlight on cancer incidence and outcome.
Researchers at City of Hope Cancer Center have successfully treated 17 out of 20 HIV-positive patients with refractory lymphoma using high-dose chemotherapy and autologous stem cell rescue. The study shows promising results with an 85% survival rate, paving the way for further investigation into this potential cure.
A USC/Norris Comprehensive Cancer Center study reveals significant differences in survival rates between HIV-related lymphoma types, including DLCL and SNC. The research suggests that optimal therapy may differ for these sub-types of disease.
Researchers analyzed 191 untreated follicular lymphoma patients and developed a model that divides patients into four groups with disparate average survival rates. The model uses gene expression patterns from non-malignant immune cells to predict patient risk, suggesting new therapeutic approaches.
A population-based case-control study found no association between SV40 exposure and increased risk of NHL. SV40 seropositivity was detected in 7-10% of patients and less than 2% of controls, indicating a possible cross-reactivity with related human polyomaviruses.
Researchers developed a new cancer treatment combining radioimmunotherapy with conventional chemotherapy, achieving complete remission in 72% of patients with follicular non-Hodgkin's lymphoma. The approach may improve treatment outcomes by targeting remaining cancer cells after chemotherapy.
Researchers developed a sequential radioimmunotherapy and chemotherapy approach, achieving a 75% overall response rate and 90% complete remission rate in patients with advanced mantle cell lymphoma. The study's findings suggest this novel treatment may be a promising advance for the disease.
A study by Rockefeller University researchers reveals that a single molecular pathway controls both cell growth and death in a type of lymphoma cancer. The NF-kappa B signaling pathway, responsible for promoting cell growth, also regulates the p53 tumor suppressor protein's function, which normally destroys harmful cells.
Researchers discovered feasible chemotherapy combinations that include trastuzumab for HER2-positive advanced breast cancer, with higher overall response rates and lower cardiac dysfunction. Two phase II clinical trials showed promising results, paving the way for future randomized phase III trials.
A study by Dr. Karen L. Syrjala found that physical recovery occurs earlier than psychological or work recovery after HCT for leukemia or lymphoma treatment. Recovery can take up to 5 years, with 84% of survivors returning to full-time work. Factors such as depression and social support before HCT can impact recovery.
Recovery after hematopoietic cell transplantation (HCT) occurs gradually over 1 to 5 years, with physical function improving earlier than psychological and work recovery. After HCT, most patients recover from treatment-related distress but may experience depression and delayed return to full-time work.
A study by Ferreri et al. found Chlamydia psittaci DNA in 80% of ocular adnexal lymphoma samples, suggesting a potential role in the disease's development. No association was found with C. trachomatis or C. pneumoniae.
Researchers found a strong association between monkey virus DNA and non-Hodgkin's lymphoma, suggesting the virus could play a role in its development. The study suggests that targeting the virus could help prevent its development and offers new therapeutic strategies.
A Yale University study found an increased risk of non-Hodgkin's lymphoma among women who began using hair-coloring products before 1980, particularly those using darker permanent products for over 25 years. The study suggests that recent changes in hair dye formula contents may have reduced the risk for newer users.
A study published in Archives of Dermatology found that people with psoriasis are at a higher risk for developing certain types of cancers, including lymphoma. The research suggests an almost three-fold increased rate of lymphoma in patients with psoriasis compared to those without the condition.
A study found that delaying chemotherapy until disease progression was equivalent to immediate treatment in overall survival and specific survival rates. Patients aged over 70 had a higher chance of not requiring chemotherapy after 10 years.
A study published in the journal AIDS found that HAART therapy can significantly prolong survival for AIDS patients with central nervous system lymphoma, with median survival of at least 22 months. This is a significant finding, as previously diagnosed patients had only a few weeks to months after diagnosis.
Researchers found that patients with a negative pretransplantation scan had a favorable outcome, with 25 still in complete remission after a median follow-up of 1,510 days. In contrast, patients with a positive scan relapsed more frequently, highlighting the potential for [F]FDG-PET to identify nonresponders.
Researchers found that AIDS-related lymphomas responding well to chemotherapy have high levels of proteins indicating rapid growth and multidrug resistance. The study also showed that suspending antiretroviral therapy during lymphoma treatment is safe and allows for high overall survival.
Research suggests that tobacco smoke exposure can transform follicular lymphoma into an aggressive large cell lymphoma with poor prognosis. Genetic mutations in the p53 tumor suppressor gene and microsatellite instability may play a role in this process.
B-lymphoproliferative disorders, such as lymphomas, cause almost a quarter of cases of massively enlarged spleens in tropical countries. Malaria is the most common cause, but unexpectedly, B-lymphoproliferative disorders are also prevalent, particularly in women younger than 40 years without raised absolute counts of lymphocytes.
A new study found that 18F-FDG PET scans accurately predict lymphoma treatment outcomes, especially after one cycle of chemotherapy. The test's sensitivity was higher after the first cycle, making it a better predictor of outcome and response to therapy.
A new study finds that passive exposure to cigarette smoke increases the risk of cancer in cats by at least double, with effects similar to those seen in humans with non-Hodgkin's lymphoma. The research also suggests a link between household smokers and increased cancer risk in pets.
Researchers found that gene swapping in mice leads to pro-B cell lymphomas, with amplifications of c-myc and IgH genes arising from chromosome translocations. The study uncovered a new mechanism for cancer formation involving the DNA-snipping enzyme RAG.
Researchers have developed a new radioimmunotherapy cancer treatment that has shown significant promise in treating mantle cell lymphoma. The study found that high-dose therapy resulted in complete remission for seven of eight patients, compared to only one of four with low-dose therapy.
A randomized study of 143 patients found that Zevalin, a new radioimmunotherapy drug, significantly improved tumor shrinkage and complete remission rates compared to standard chemotherapy. The study results demonstrate the effectiveness of Zevalin in treating B cell non-Hodgkin’s lymphoma.
Recent studies confirm presence of SV40 DNA in human lymphoma samples, suggesting possible vaccine-related transmission. The findings have significant implications for understanding cancer development and prevention.
Researchers found that brief cycles of high-dose chemotherapy produced long-term disease-free survival in more than half of adults treated for Burkitt's small non-cleaved lymphoma and leukemia. The regimen achieved an 80% complete response rate, with 52% of patients remaining in continuous remission after five years.
UCLA researchers have discovered a unique gene modification that may be the cause of certain types of lymphoma. The discovery, which involves DNA methylation, could lead to new treatments for these types of cancer.
The Leukemia & Lymphoma Society has awarded $22.5 million in grants to three interdisciplinary research teams aiming to accelerate the discovery of new treatments for leukemia, lymphoma, and myeloma. The teams will focus on patient-specific therapies, genetic lesions, and molecular biology approaches.
A Phase III study found significant improvements in overall survival, disease-free status, and complete remission rates for patients with aggressive non-Hodgkin's lymphoma treated with MabThera and CHOP chemotherapy. Survival at 1-year was 83% for the rituximab combination therapy group compared to 68% for those receiving CHOP alone.
Researchers found that HIV inactivates a tumor suppressor gene, contributing to Burkitt's lymphoma development. The study suggests a new mechanism linking HIV and the disease.